Shares of Atyr Pharma Inc. (NASDAQ:LIFE) saw unusually-high trading volume on Monday . Approximately 537,577 shares traded hands during trading, an increase of 35% from the previous session’s volume of 399,269 shares.The stock last traded at $3.69 and had previously closed at $3.42.

LIFE has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Atyr Pharma from a “sell” rating to a “buy” rating and set a $3.50 price target on the stock in a report on Tuesday, May 31st. Citigroup Inc. raised their price target on shares of Atyr Pharma from $3.00 to $4.00 and gave the company a “neutral” rating in a report on Tuesday. JPMorgan Chase & Co. cut their price target on shares of Atyr Pharma from $15.00 to $10.00 and set an “overweight” rating on the stock in a report on Thursday, August 11th. Finally, BMO Capital Markets restated a “hold” rating on shares of Atyr Pharma in a report on Thursday, May 12th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Atyr Pharma presently has an average rating of “Hold” and a consensus target price of $6.00.

The stock’s market cap is $81.35 million. The company has a 50-day moving average of $2.99 and a 200 day moving average of $3.71.

Atyr Pharma (NASDAQ:LIFE) last issued its quarterly earnings data on Wednesday, August 10th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.71) by $0.06. Analysts expect that Atyr Pharma Inc. will post ($2.63) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Atyr Pharma stock. RS Investment Management Co. LLC boosted its position in shares of Atyr Pharma Inc. (NASDAQ:LIFE) by 11.5% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,206,249 shares of the company’s stock after buying an additional 124,000 shares during the period. RS Investment Management Co. LLC owned about 5.10% of Atyr Pharma worth $11,857,000 as of its most recent SEC filing.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.